FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer | FDA@ great news for our patients ⁦@MayoClinic⁩ ⁦@shilpaonc⁩ ⁦@PGrivasMDPhD⁩

Team America 🇺🇸 🇨🇦 have their educational video - with novel soundtrack - for Uromigos cup 🏆. Eurasia is winning. ♥️ =points. Surely it’s time for a win for the Americas. #UromigosLive @OncoAlert @montypal

https://t.co/frAWPjfrxr Sharing the link again

Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!

Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis -sharing Mayo Clinic experience with EV Pembro , consistent with phase III trial,also in patients on dialysis

#ESMO25 @shilpaonc @neerajaiims great summary of abstracts with need to combine FGFR3i with EVP @PGrivasMDPhD

Had a great time hosting @BrainTumorDoc learning about treatment of brain mets which we all deal with in our patients @neerajaiims @VivekSubbiah @MayoClinicME @IrbazRiaz

SWOG members headed to Chicago for #SWOGonc fall mtg, Sep 18-20! Kickoffs for S2427 BRIGHT & Triple Switch, talks on ⬆️ enrollment of older & rural patients, plenary reflecting on progress in public-powered #CancerResearch, #NCORP trials wkshp, much more! https://t.co/vgWTgOyANq

Great Honor hosting Tom Flaig for grand rounds at Mayo Clinic ⁦@MayoClinic⁩ ⁦@GIcancerDoc⁩

@shilpaonc @MaxKates @BladderCancerUS @IBCG_BladderCA @WorldBladderCan @MattGalsky @montypal @neerajaiims @UrogerliMD @AbhiTrip87 @arkhaki Such an outstanding #BCANTT25 - always love the multi-D, patient-centered conversations that happen at this meeting @shilpaonc @MaxKates! Thank you for the opportunity to discuss financial toxicity with all stakeholders at the table!

Meeting colleagues mentors and mentees #BCANTT25

@RuchikaTalwarMD gives a great talk on financial toxicity (objective costs + hard to measure “subjective aspects”) for patients with #bladdercancer excellent session @Parminder1699 @BladderCancerUS @shilpaonc @arkhaki @JasonBrownMDPhD @MaxKates @DrKarineTawagi @HibaMKhanMD

Great learning experience as always my fav Bladder cancer meeting #BCANTT25 great sessions put together by @MaxKates and @shilpaonc . Meeting mentors and helping junior investigators. looking forward to next year as Co-Chair with Max Kates #BCANTT26

#BCANTT25 Balancing innovation and affordability: What a great session by Matt, Ruchika Talwar, Rich Toner and Stephanie Spence @shilpaonc @PGrivasMDPhD @MaxKates

@Parminder1699 sharing his experience and insights from S1806 #bcantt25 @BladderCancerUS

Excited to have @slernerbcmedu1 & @apolo_andrea kick off the session on “Lessons Learned from Clinical Trials” at #BCANTT25 @BladderCancerUS. Looking forward to insights from a stellar lineup of Principal Investigators behind key trials—positive, negative, and unfinished. Every

Wonderful insights from clinical trials - both positive and negative, with pros and cons- at @BladderCancerUS #bcantt25 co-chaired by @apolo_andrea @nciccr_gmb and Seth Lerner @DrRosenbergMSK @JCensits @Parminder1699

#BCANTT25 moving the field forward what after EV-P in bladder. @PGrivasMDPhD @arkhaki @siadaneshmand

#insurance denial - How do you respond to insurance denial when they state that approval of Enhertu in bladder cancer was based on small phase II and the insurance would not accept this approval

🚨 NEW in European Urology! A living meta-analysis reveals heterogeneity in PARP inhibitor efficacy for mCRPC. 🔍 BRCA-altered tumors = most benefit ⚠️ No clear advantage in ATM/CHEK2 🧬 Gene-by-gene insights 📖 Read now: https://t.co/Yy708oBba3 #ProstateCancer #PARP #mCRPC